Christine Siu
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
Mevrouw Christine E. Siu is Chief Operating Officer bij BridgeBio Pharma, Inc. Zij zetelt in de Raad van Bestuur van Vividion Therapeutics, Inc. en Monte Rosa Therapeutics, Inc. Mevrouw Siu was voorheen werkzaam als Chief Financial & Accounting Officer bij Eidos Therapeutics, Inc., als Chief Business Officer bij The Bluefield Project to Cure Frontotemporal Dementia, als Senior Director-Operations & Business Development bij Global Blood Therapeutics, Inc., als Principal bij Third Rock Ventures LLC, als Vice President bij Thomas, McNerney & Partners LLC, als Analist bij Bear, Stearns & Co., Inc., en als Portfolio Manager bij Warburg Pincus LLC. Zij was ook lid van de raad van bestuur van NeuroTherapeutics Pharma, Inc. Zij behaalde haar doctorale graad aan de Universiteit van Michigan en een MBA aan de Harvard Business School.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-06-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-12-2020 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Directeur/Bestuurslid | 04-05-2021 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Directeur/Bestuurslid | 10-06-2021 |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Directeur/Bestuurslid | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| BRIDGEBIO PHARMA, INC. | Operationeel Directeur | 23-07-2024 |
| EIDOS THERAPEUTICS, INC. | Financieel Directeur/CFO | 31-12-2019 |
The Bluefield Project to Cure Frontotemporal Dementia
The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | Corporate Officer/Principal | 01-01-2017 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Operationeel Directeur | 01-01-2014 |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Private Equity Analist | 31-12-2010 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 15 |
|---|---|
Bear, Stearns & Co., Inc.
Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Provides investment banking, securities trading and brokerage Services | Finance |
Warburg Pincus LLC
Warburg Pincus LLC Investment ManagersFinance Warburg Pincus invests in companies located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for buyout transactions. | Finance |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Finance |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
NeuroTherapeutics Pharma, Inc.
NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical and therapeutic drugs for central nervous system disorders | Health Technology |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Bluefield Project to Cure Frontotemporal Dementia
The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau